SCHEMBL2038078

SCHEMBL2038078

COCN1CCCC1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.47
RAB9A P51151 1/20 0.44
ACE P12821 7/20 0.41
REN P00797 3/20 0.41
LMNA P02545 2/20 0.41
HSD17B10 Q99714 2/20 0.41
CYP2C19 P33261 2/20 0.41
KDM4E B2RXH2 1/20 0.41
F2 P00734 1/20 0.41
LTA4H P09960 1/20 0.41
MAPT P10636 1/20 0.41
PEPD P12955 1/20 0.41
ALOX15 P16050 1/20 0.41
PTGS1 P23219 1/20 0.41
HTR2A P28223 1/20 0.41
PTGS2 P35354 1/20 0.41
HRH1 P35367 1/20 0.41
THPO P40225 1/20 0.41
PMP22 Q01453 1/20 0.41
ACE2 Q9BYF1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13555216 1.00 SMN1; SMN2 (0.47) SMN1; SMN2RAB9AACERENLMNA
SCHEMBL4555126 0.84 SPHK1 (0.40) SMN1; SMN2RAB9ALMNAKDM4E
SCHEMBL18555352 0.84 SPHK1 (0.40) SMN1; SMN2RAB9ALMNAKDM4E
SCHEMBL4959163 0.82 LTA4H (0.45) SMN1; SMN2RAB9AACELTA4HSLC6A1
SCHEMBL4959171 0.82 LTA4H (0.45) SMN1; SMN2RAB9AACELTA4HSLC6A1
SCHEMBL6568062 0.82 LTA4H (0.45) SMN1; SMN2RAB9AACELTA4HSLC6A1
SCHEMBL17416357 0.81 HSD17B10 (0.45) SMN1; SMN2RAB9AACERENLMNA
SCHEMBL6523272 0.80 SMN1; SMN2 (0.40) SMN1; SMN2LMNAHSD17B10CYP2C19
SCHEMBL16418017 0.80 SMN1; SMN2 (0.43) SMN1; SMN2RAB9AACERENLMNA
SCHEMBL8283493 0.79 SMN1; SMN2 (0.45) SMN1; SMN2RAB9AACERENLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023183405-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2023-09-28 WO disclosed
EP-2852587-A1 ANTIVIRAL COMPOUNDS WITH AN IMIDAZOLE - BIPHENYL - IMIDAZOLE CORE Gilead Sciences, Inc. (US) 2015-04-01 EP disclosed
WO-2013173492-A1 ANTIVIRAL COMPOUNDS WITH AN IMIDAZOLE - BIPHENYL - IMIDAZOLE CORE GILEAD SCIENCES, INC. (US) 2013-11-21 WO disclosed
EP-2640719-A2 ANTIVIRAL COMPOUNDS Gilead Sciences, Inc. (US) 2013-09-25 EP disclosed
EP-2509971-A1 NEW PROCESS FOR THE PREPARATION OF DRONEDARONE SANOFI (FR) 2012-10-17 EP disclosed
WO-2012068234-A2 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-05-24 WO disclosed
WO-2011073376-A1 PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERSAS AS AGONISTS OF G- PROTEIN COUPLED RECEPTOR 43 (GPR43) EUROSCREEN S.A. (BE) 2011-06-23 WO disclosed
WO-2011070380-A1 NEW PROCESS FOR THE PREPARATION OF DRONEDARONE SANOFI-AVENTIS (FR) 2011-06-16 WO disclosed